first group presented clinical and laboratory evidence of inactive rheumatic heart disease. The second group consisted of patients with rheumatoid arthritis, diagnosed by the criteria of the American Rheumatism Association.14) One patient with lupus erythematosus was also tested with the same procedure. The control group consisted of patients free of cardiovascular and rheumatic diseases. The length of interval between cessation of steriod therapy and Metopirone administration was at least 1 month, because post-therapeutic rebounds usually occurred within 2 weeks and were rare beyond 4 weeks after discontinuance of steroid treatment.4) Metopirone was supplied by Ciba, Basel. In order to reactivate rheumatic inflammation patients received Metopirone 2Gm. per day orally for 5 days. During the study patients were observed for changes in clinical status and laboratory tests. With an ophthalmologic slit lamp small blood vessels were observed for the presence of blood sludge in the bulbar conjunctiva. Red cell sedimentation rate was measured by Westergren method. C-reactive protein, antistreptolysin-O titer, RA test for rheumatoid factor, LE test for antinuclear antibodies, TA test for antithyroglobulin antibodies etc. were examined with reagents purchased from the Hyland Laboratories. Urinary levels of 17-ketosteroids were determined by the method of Norymberski, and 17-hydroxycorticosteroids by the modifications of the method of Porter-Silber. The normal 24-hour urinary excretion of 17-KS ranges from 5 to 15mg. and that of 17-OHCS from 1 to 10mg. After receiving Metopirone the maximal response in urinary steroids was observed on one of the 5 test days and the following day after Metopirone administration has been terminated. The peak values were compared to previous levels of urinary 17-KS and 17-OHCS. Table I and II show clinical situations before, during and after Metopirone administration.
RESULTS

Clinical Changes due to Metopirone Administration
Before beginning of the test, all of 8 patients with rheumatic heart disease had some of cardiac manifestation, including palpitation, exertional and nocturnal dyspnea, headache, and dizziness, associated with cardiac enlargement, murmurs, electrocardiographic abnormalities etc. One patient suffering from mitral stenosis and insufficiency occasionally complained of arthralgia, but none of them exhibited the presence of rheumatic activity. During Metopirone administration 1 patient with aortic and mitral regurgitation (Case 3) developed nocturnal dyspnea and palpitation, which he had not had before, on the third day of the test, and these manifestations subsided spontaneously on the sixth day after Metopirone was ended. Another patient with mitral stenosis and insufficiency (Case 7) complained of arthralgia on the fourth day after Metopirone was discontinued. The third patient with mitral insufficiency (Case 8) developed low grade fever on the following day after the test. His general conditions seemed to be improved during and after Metopirone treatment, but he died a sudden Jap. Heart J. N ovember, 1964 Jap. Heart J. November, 1964 In rheumatoid arthritis all of 5 patients had apparent intravascular sludging before Metopirone administration, and the pre-existing finding was aggravated in all of them during and after the medication. In a patient suffering from lupus erythematosus blood sludge in the conjunctiva existed initially and was enhanced after the test. By contrast none of 6 patients in the control group, except one, had the vascular finding previously, and none of them exhibited appearance or enhancement of blood sludge after receiving the drug.
In summary positive response of blood sludge to Metopirone was, therefore, found in 4 of 8 patients with rheumatic heart disease, all of 5 with rheumatoid arthritis, one with lupus erythematosus, and none of 6 in the control group.
The Effect of Metopirone upon Serum Protein: During and after Metopirone administration the values of serum total protein decreased in 5 of 8 patients with rheumatic heart disease and one with lupus erythematosus, but in none of total 11 with rheumatoid arthritis and control diseases. The increase of serum gamma globulin level was observed after receiving Metopirone in 5 of 6 patients in the control group, 3 of 5 with rheumatoid arthritis, 1 with lupus erythematosus, and none with rheumatic heart disease. The values of serum gamma globulin fell in 7 of 8 patients with rheumatic heart disease, 2 of 5 with rheumatoid arthritis, but in none in control subjects.
The Changes in Urinary 17-KS before and after Administration of Metopirone:
The urinary level of 24-hour 17-ketosteroids excretion before Metopirone treatment was lower than normal in 5 of 8 patients with rheumatic heart disease, 2 of 5 with rheumatoid arthritis, none with lupus erythematosus, and 2 of 6 in the control group. If more than two-fold rise of urinary 17-KS level was considered normal response to Metopirone, abnormal response was found in 2 of 8 patients with rheumatic heart disease, 3 of 5 with rheumatoid arthritis, 1 with lupus erythematosus, and 4 of 6 in the control group.
The Changes in Urinary 17-OHCS before and after Metopirone Administration:
The 24-hour level of 17-hydroxycorticosteroids was lower than normal initially in 3 of 8 patients with rheumatic heart disease, 3 of 6 in control patients, none of 5 with rheumatoid arthritis, and 1 with lupus erythematosus. If a normal response is characterized by the doubling or more of the previous level, abnormal reaction to Metopirone was observed in 3 of 8 patients with rheumatic heart disease, 3 of 5 with rheumatoid arthritis, 1 with lupus erythematosus, and none of 6 with control diseases.
The correlation of abnormal response of urinary 17-OHCS to changes in clinical status or blood sludge in the bulbar conjunctiva was examined after receiving Metopirone. Of 10 patients with positive sludge reaction, 5 ex- In order to prove the latter explanation, patients should be treated with exogen-ous ACTH and examined for urinary levels of 17-OHCS. In rheumatoid arthritis the possibility exists that hypofunction of adrenal cortex has been brought about by a long-term treatment with adrenocorticosteroids, although urinary level of 17-OHCS was not lower than normal in our patients with the disease. In this study the ACTH test has not been performed. It is noted that some relationship is established, after Metopirone treatment, between abnormal response of the levels of 17-OHCS in the urine and positive reaction in blood sludge in the bulbar conjunctiva. Subclinical rheumatic lesions may be present in the pituitary or adrenal glands, accompanying abnormal response to Metopirone.
Following Metopirone administration a variety of rheumatic manifestations appeared in rheumatic heart disease, consisting of cardiac failure, fever, and arthralgia. In the control patients appearance of manifestations or aggravation of pre-existing symptoms and signs could not be found after Metopirone treatment.
The clinical response to Metopirone appeared following more than 3 days' administration of the drug, and persisted for 5 days or more. In our initial studies the drug was given according to the conventional schedule of Metopirone test, 2 or 3Gm. orally in 24 hours,12) but significant changes could not be obtained of clinical and laboratory aspects. Clinical abnormalities occurred, when the period of administration was prolonged up to 5 days with daily doses of 2Gm. orally. The clinical manifestations exhibited by Metopirone might be suspected to be the side effects of Metopirone, and not due to activated subclinical lesions. But the side effects of the drug have been reported to be minimal, consisting of vertigo and dizziness following rapid absorption of Metopirone. In this report some patients had anorexia, nausea, vomiting, and diarrhea, which were supposed due to direct effects of Metopirone to alimentary tract. On the basis that Metopirone is capable of suppressing blood cortisol levels and consequently activates subclinical mild inflammation, it is clear that above-mentioned manifestations, except gastrointestinal ones, are due to reactivation of rheumatic activity in rheumatic heart disease. This procedure may aid to detect the presence of subclinical rheumatic lesions and to decide whether a valvular heart disease is rheumatic or not.
By Metopirone, inflammation other than rheumatic can be also activated. In our study Metopirone administration was followed by arthralgia in rheumatoid arthritis and fever in lupus erythematosus. In our control patients with pulmonary tuberculosis, nephritis, gastritis, and cholecystitis, which are considered to be inflammatory changes, signs and symptoms due to activated inflammation, however, were not found after Metopirone treatment. No evidence has been obtained in our study to prove, that failure of clinical res-ponse to Metopirone necessarily means the absence of subclinical inflammatory changes in the patient.
Our previous studies suggested that residual vascular lesions remain, even when clinical signs and symptoms of acute rheumatic fever are absent in the patient. These vascular abnormalities have been observed by us in the biopsies removed from the knee joints and in the conjunctiva with biomicroscopy.15), 16) In small blood vessels of the bulbar conjunctiva one of the most frequent findings was sludged blood described Knisely.11) In this phenomenon circulating red cells have been observed to form aggregates of varying size and firmness in a number of pathologic states. Their production has been correlated with increases in the concentration of globulin and fibrinogen in blood and with the presence of high molecular weight dextran. This tendency to clump probably reflects the composition of the coating on the surface of red cells.1) In our study the presence of blood sludge appeared to be the most sensitive index among measures available for the presence of inflammatory changes, which may be rheumatic or of other origin.
There remains a question whether this procedure with Metopirone can be applied to patients as a conventional test for subclinical disease process. In this study 1 patient with mitral insufficiency died a sudden death 7 days after Metopirone medication was ended (Case 8). His urinary level of 17-OHCS was only 0.6mg. per day, but responded normally to the drug. The evidence to indicate that the cause of his death was ascribed to Metopirone could not be obtained, because he was in a state of congestive heart failure previously, exhibiting a variety of manifestations. Postmortem examination revealed that he was accompanied by ventricular septal defect in addition to mitral valvular involvement. It has been suggested that patients with minimally functioning adrenals may develop acute adrenal insufficiency when given Metopirone. Metopirone should not be administered, therefore, to patients with adrenal insufficiency and after long-term treatment with steroids.
This procedure for rheumatic activity in rheumatic heart disease should be performed with caution for the present.
SUMMARY
In order to detect subclinical mild rheumatic inflammation, Metopirone, or SU-4885, was administered to patients with rheumatic heart disease, in an inactive stage of rheumatic fever. Metopirone lowers blood cortisol levels and activates suppressed inflammatory changes of the disease. Following Metopirone administration clinical manifestations, such as cardiac symptoms, arthralgia and fever, occurred in 3 of 8 patients with rheumatic heart disease, Jap. Heart J. November, 1964 and blood sludge in the bulbar conjunctiva appeared or was enhanced in severity and range in 4 of them. These manifestations are considered to be due to subclinical inflammatory changes activated by Metopirone in rheumatic heart disease. The same procedure was performed in patients with rheumatoid arthritis, lupus erythematosus, and other diseases. Of 5 patients with rheumatoid arthritis, arthralgia was aggravated in 2 patients, cardiac symptoms occurred in 1, and enhancement of blood sludge in the bulbar conjunctiva was found in all of them.
It was suggested that this procedure may aid to detect subclinical rheumatic activity in rheumatic heart disease, and to determine a valvular heart disease whether of rheumatic origin or not.
